ArticleClinical transplantation2026
Impact of the 2024 Organ Procurement and Transplantation Network Kidney Donor Profile Index Rescoring on Donor Kidney Utilization and Allocation out of Sequence: A one-Year Analysis.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn October 2024, the Organ Procurement and Transplantation Network (OPTN) removed hepatitis C virus (HCV) positivity and African American/Black (AA/B) donor race from the Kidney Donor Profile Index (KDPI) calculation. This study evaluates the early impact of this policy change on kidney utilization during its first year.
methodsWe performed a retrospective analysis of OPTN data for organ procurements and adult deceased-donor kidney transplants between November 2023 and October 2025. Donors were stratified by HCV status and race. Kidney utilization and allocation out-of-sequence (AOOS) were compared between pre-policy (November 2023-October 2024) and post-policy (November 2024-October 2025) periods.
resultsThe policy revision was associated with redistribution of HCV+ and AA/B donor kidneys toward lower KDPI category, with increases of 989% and 144%, respectively, in the 0-20% KDPI range. Overall utilization increased among AA/B (66.9% to 71.5%), non-AA/B (70.1% to 72.1%), HCV- (69.6% to 72.0%), and HCV+ donors (70.3% to 72.5%). However, utilization within individual KDPI categories declined for AA/B and HCV+ donors across most strata, except for the 21-34% category among HCV+ donors. AOOS decreased from 20.2% to 16.8% (absolute reduction 3.4%; 95% confidence interval, -4.1% to -2.6%).
conclusionThe policy was associated with increased overall utilization across donor groups. However, gains among AA/B and HCV+ donors appear primarily driven by redistribution into different allocation sequences rather than improvement in within-category utilization. Reduced AOOS suggests improved allocation efficiency, though findings may be influenced by concurrent regulatory changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.